AdvisorShares Psychedelics ETF
PSILDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 29, 2025 | $1.68 | 2025-12-22 | 2025-12-22 |
| September 29, 2025 | $0.02 | 2025-09-22 | 2025-09-22 |
| June 27, 2025 | $0.01 | 2025-06-23 | 2025-06-23 |
| March 28, 2025 | $0.16 | 2025-03-21 | 2025-03-21 |
| December 30, 2024 | $0.05 | 2024-12-23 | 2024-12-23 |
Dividends Summary
- Consistent Payer: AdvisorShares Psychedelics ETF has rewarded shareholders with 8 dividend payments over the past 3 years.
- Total Returned Value: Investors who held PSIL shares during this period received a total of $2.10 per share in dividend income.
- Latest Payout: The most recent dividend of $1.68/share was paid 201 days ago, on December 29, 2025.
- Yield & Schedule: PSIL currently pays dividends quarterly with an annual yield of 7.79%.
- Dividend Growth: Since 2022, the dividend payout has grown by 3006.3%, from $0.05 to $1.68.
Company News
Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with hi...
The cannabis industry is awaiting a decision on rescheduling cannabis, which could impact its financial and regulatory landscape. The psychedelics industry is navigating the aftermath of a setback in MDMA research for PTSD, leading to potential consolidation and strategic shifts.
We have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.
Technology remained the best-performing sector of the second quarter on the AI drive while energy lagged.
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ...
